Tirzepatide CAS2023788-19-2 TR10 TR5 TR15 RT10 RT20 RT30
TDS 2103 Inquiries
2023788-19-2
Pharmaceutical Grade
99%
shenzhen
SC
10 mg / 15mg/ 20 mg / 30 mg / 10 tubes per box
Yes
2027-01-20
tr
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Certificates-
TDS
Basic Info-
Product Name:
Tirzepatide
Other Name:LY3298176;
CAS No.:2023788-19-2
Molecular Formula:C225H348N48O68
Molecular Weight:4813
EC Number:200-001-8
Categories:
Characteristics-
Appearance:
White to off-white
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
tr
-
Location:
B27 SHING LEE COMM BLDG 8WING KUT ST CENTRAL HONGKONG
-
Average lead Time:
1 days
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Inquiry History2103 Inquiries
Country Product Purchase Quantity Date Posted
Brazil
Tirzepatide
100 G Oct 28, 2026
Belgium
Tirzepatide
10 MG Oct 28, 2026
United States
tirzepatide
100 MG Oct 28, 2026
United States
Tirzepatide
60 MG Oct 28, 2026
United States
Tirzepatide
10 PCS Oct 28, 2026
United States
tirzepatide
30 MG Oct 27, 2026
United States
Tirzepatide
40 MG Oct 27, 2026
Philippines
Tirzepatide
2 MT Oct 27, 2026
Philippines
Tirzepatide
30 MG Oct 26, 2026
Slovakia
Tirzepatide
1 G Oct 26, 2026
France
Tirzepatide
1 KG Oct 25, 2026
United States
Tirzepatide
2.5 MG Oct 25, 2026
United Kingdom
Tirzepatide
5 MT Oct 25, 2026
United Kingdom
Tirzepatide
6 MT Oct 24, 2026
Peru
tirzepatide
10 MG Oct 21, 2026
Puerto Rico
tirzepatide
40 MG Oct 21, 2026
United States
Tirzepatide
10 MT Oct 21, 2026
South Africa
Tirzepatide
1 MT Oct 20, 2026
United States
Tirzepatide
5 KG Oct 20, 2026
United States
tirzepatide
30 MG Oct 20, 2026 Post an enquiry for this product
More from this Seller
-
-
-
5-amino fat-burning weight loss product. Peptide powder for freezing is produced in China.
Pharmaceutical Grade / 99%
$1/G FOB
-
-
-
-
IGF-1L TR50 LC216 2S50 CJC NO DAC 5mg + IPA5mg P20 SM10 BAC SMO10 TSM5 ET50 RT10
Pharmaceutical Grade / 99%
$1/G FOB
-
-
-
-
LYSINE-PROLINE-VALINE MOTS-c SLU-PP-322 Epithalon 2S10 2S50 MT1 ML10 OT2
Pharmaceutical Grade / 99%
$1/G FOB
-
-
-
-
BT10 375 CU50 CU100 NAD+ Glutathione CAS1415456-99-3 LC216 LC526 LC600
Pharmaceutical Grade / 99%
$1/G FOB
-
